[1] |
FENG Xinying, WANG Bing, LIU Peifeng.
Innovations and challenges in intraperitoneal chemotherapy for peritoneal metastatic carcinoma
[J]. China Oncology, 2024, 34(9): 827-837.
|
[2] |
CAO Xiaoshan, YANG Beibei, CONG Binbin, LIU Hong.
The progress of treatment for brain metastases of triple-negative breast cancer
[J]. China Oncology, 2024, 34(8): 777-784.
|
[3] |
LIAO Ziyi, PENG Yang, ZENG Beilei, MA Yingying, ZENG Li, GAN Kelun, MA Daiyuan.
Analysis of pathological remission degree and influencing factors of radical surgery after neoadjuvant immunotherapy combined with chemotherapy in patients with locally advanced esophageal squamous cell carcinoma
[J]. China Oncology, 2024, 34(7): 669-679.
|
[4] |
HUANG Sijie, KANG Xun, LI Wenbin.
Clinical research progress of intrathecal therapy in the treatment of leptomeningeal metastasis
[J]. China Oncology, 2024, 34(7): 695-701.
|
[5] |
ZHANG Ruoxin, YE Zilan, WENG Junyong, LI Xinxiang.
Correlation study between advanced age and inferior prognosis in stage Ⅱ colorectal cancer patients
[J]. China Oncology, 2024, 34(5): 485-492.
|
[6] |
SHI Jialu, ZHU Tingting, TAO Xiang, MA Fenghua, LIN Zhi, SHAO Jun, ZHAO Yuqing.
Retrospective analysis of 12 cases of low grade extrauterine endometrial stromal sarcoma and literature review
[J]. China Oncology, 2024, 34(4): 418-424.
|
[7] |
XU Yonghu, XU Dazhi.
Progress and prospects of gastric cancer treatment in the 21st century
[J]. China Oncology, 2024, 34(3): 239-249.
|
[8] |
LU Yue, LU Renquan, ZHANG Jie, ZHENG Hui.
Application value of combined coagulation function indicators in monitoring hypercoagulable state of patients with colorectal cancer after chemotherapy
[J]. China Oncology, 2024, 34(3): 278-285.
|
[9] |
QU Guolun, ZHANG Ruming, CHEN Yong, QU Xinglong, ZHANG Hongqiang, WANG Hongbo, WANG Kangwei, PENG Shuai.
Surgical margin and efficacy evaluation of barrier resection for soft tissue sarcoma of extremities in 72 cases
[J]. China Oncology, 2024, 34(3): 293-298.
|
[10] |
CHEN Yifan, LI Ting, WANG Biyun.
Research progress of CCR8 in tumor immunotherapy
[J]. China Oncology, 2024, 34(3): 299-305.
|
[11] |
HU Xiaoyu, CAI Yuwen, YE Fugui, SHAO Zhimin, HU Weigang, YU Keda.
Impact of BRCA1/2 germline mutation on the incidence of second primary cancer following postoperative radiotherapy in patients with triple-negative breast cancer
[J]. China Oncology, 2024, 34(2): 185-190.
|
[12] |
LIU Zhiyu, XU Dong, CHEN Xihao, LI Jipeng.
Influencing factors and establishment of a prediction model for the tumor regression after neoadjuvant chemoradiotherapy in locally advanced rectal cancer
[J]. China Oncology, 2024, 34(2): 191-200.
|
[13] |
FENG Huizhi, LIU Jingmei, BU Xiaoqian.
A retrospective study of pembrolizumab combined with XELOX regimen in the treatment of advanced gastric cancer
[J]. China Oncology, 2024, 34(11): 1028-1035.
|
[14] |
CHEN Hongyu, SU Pengyu, LUO Wenzi, PANG Dequan, WANG Feiran.
A study of relationship between cardiac exposure dose-volume and cardiovascular autonomic dysfunction in radiotherapy
[J]. China Oncology, 2024, 34(11): 1036-1044.
|
[15] |
CHU Yajuan, ZHANG Lei, LI Yunhai, LUO Weiming, ZHANG Jing, MO Xiaochen, MA Jinli.
Exploring the attenuating effect of amifostine on neoadjuvant radiotherapy with concurrent use of irinotecan for locally advanced rectal cancer: a retrospective cohort study of 154 cases
[J]. China Oncology, 2024, 34(10): 957-965.
|